Researcher
Séverine Vermeire
- Disciplines:Endocrinology and metabolic diseases, Gastro-enterology and hepatology, Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Oct 1999 → Today
Projects
1 - 10 of 63
- Development of new strategies for value-based care in chronic inflammatory bowel diseases.From5 Dec 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Gut functional and inflammatory disorders: biomarker and therapeutic target discovery (GUT-FIRE)From10 Jul 2023 → TodayFunding: IOF - mandates
- Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseasesFrom1 Apr 2023 → TodayFunding: HORIZON.2.1 - Health
- Development, Validation, and Valorization of a Patient Preference Platform to Inform Healthcare Decision-MakingFrom1 Mar 2023 → TodayFunding: IOF - technology validation in lab
- Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseasesFrom15 Feb 2023 → TodayFunding: BOF - projects
- Characterization of triggers of post-operative recurrence in Crohn’s disease in both the external and luminal side of the intestineFrom1 Jan 2023 → TodayFunding: FWO research project
- Development of a gut-on-a-chip model for pre-clinical testing of drugs for inflammatory bowel diseaseFrom12 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseasesFrom15 Jun 2022 → TodayFunding: BOF - various
- Host-microbe interaction in intestinal homeostasis: unravelling the mechanisms involved in the onset of multiple inflammationrelated diseasesFrom1 Jan 2022 → TodayFunding: FWO EOS
- Histological healing in inflammatory bowel diseaseFrom1 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
Publications
811 - 820 of 1016
- Variants of NOD1 and NOD2 genes display opposite associations with familial risk of crohn's disease and anti-saccharomyces cerevisiae antibody levels(2012)
Authors: Séverine Vermeire
Pages: 430 - 438 - Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro(2012)
Authors: Ingrid Arijs, Gert De Hertogh, Séverine Vermeire, Paul Rutgeerts
Pages: 401 - 8 - Malignancies and mortality in 200 patients with primary sclerosering cholangitis: a long-term single-centre study(2012)
Authors: Johan Fevery, Liesbet Henckaerts, Robin Van Oirbeek, Séverine Vermeire, Paul Rutgeerts, Frederik Nevens, Werner Van Steenbergen
Pages: 214 - 22 - Cancer in inflammatory bowel disease 15 years after diagnosis in a population-based European Collaborative follow-up study. Erratum(2012)
Authors: Konstantinos H Katsanos, Athina Tatsioni, Natalia Pedersen, Mary Shuhaibar, Vicent Hernandez Ramirez, Patrizia Politi, Evelien Ronnbrechts, Marieke Pierik, Juan Clofent, Marina Beltrami, et al.
Pages: 132 - 133 - Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial(2012)
Authors: Gert Van Assche, Séverine Vermeire, Vera Ballet, Niels Vande Casteele, Ann Gils, Paul Rutgeerts
Pages: 229 - 34 - Association of a Functional Variant in the Wnt CoReceptor LRP6 with Early Onset Ileal Crohn's Disease(2012)
Authors: Séverine Vermeire, Paul Rutgeerts
- Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment(2012)
Authors: Niels Vande Casteele, Gert Van Assche, Paul Rutgeerts, Séverine Vermeire, Ann Gils
Pages: 321 - Genetic variants in autophagy-related genes and granuloma formation in a cohort of surgically treated Crohn's disease patients(2012)
Authors: Séverine Vermeire, Isabelle Cleynen, Bart Lemmens, Xavier Sagaert, Liesbet Henckaerts, Gert Van Assche, Karel Geboes, Paul Rutgeerts, Gert De Hertogh
Pages: 43 - 50 - How do we Identify Patients Needing Early Aggressive Therapy and what Should we Use?(2012)
Authors: Marc Ferrante, Séverine Vermeire
Pages: 117 - 119 - Infliximab therapy for pediatric Crohn disease and Ulcerative Colitis(2012)
Authors: Ilse Hoffman, Séverine Vermeire, Gert Van Assche, Peter Witters, Paul Rutgeerts
Pages: 345 - 355
Patents
1 - 10 of 10
- Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis (Inventor)
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- A new inflammation associated, low cell count enterotype (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- A new inflammation associated, low cell count enterotype (Inventor)
- Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis (Inventor)
- Biomarker panel for assessment of mucosal healing (Inventor)
- METHODS FOR PREDICTING POST-OPERATIVE RECURRENCE OF CROHN'S DISEASE (Inventor)